Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status approved; investigational
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
UNII LR24G6354G
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.0010.001086%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000112%
Pyrexia08.05.02.0030.004623%
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000336%
Renal failure20.01.03.005--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Sepsis11.01.11.003--
Skin disorder23.03.03.007--Not Available
Skin ulcer23.07.03.003; 24.04.03.0070.000112%
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.000224%
Stomatitis07.05.06.0050.002429%
Tachycardia02.03.02.0070.000504%Not Available
Thirst14.03.02.007; 08.01.09.0210.000112%Not Available
Thrombocytopenia01.08.01.0020.002496%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Vertigo04.04.01.003; 17.02.12.0020.000638%
VIth nerve paralysis17.04.02.002; 06.05.02.0090.000112%Not Available
Vocal cord paralysis22.04.01.002; 17.04.06.0020.000112%
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Hypoacusis04.02.01.0060.000224%
Brain oedema12.01.10.010; 17.07.02.0030.000112%
Neutropenic sepsis11.01.11.006; 01.02.03.007--Not Available
General physical health deterioration08.01.03.0180.001063%Not Available
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages